Seth P Lerner
Overview
Explore the profile of Seth P Lerner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
274
Citations
9360
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Narayan V, Boorjian S, Alemozaffar M, Konety B, Shore N, Gomella L, et al.
J Urol
. 2024 May;
212(1):74-86.
PMID: 38704840
Purpose: Nadofaragene firadenovec-vncg is a nonreplicating adenoviral vector-based gene therapy for bacillus Calmette-Guérin (BCG)-unresponsive carcinoma in situ (CIS) with/without high-grade Ta/T1. We report outcomes following 5 years of planned follow-up....
22.
Pal S, Grivas P, Gupta S, Dizman N, Zengin Z, Valderrama B, et al.
Eur Urol
. 2024 Apr;
87(2):271-274.
PMID: 38580518
No abstract available.
23.
Parikh M, Tangen C, Hussain M, Gupta S, Callis S, Jo Y, et al.
Eur Urol Oncol
. 2024 Mar;
7(5):1097-1104.
PMID: 38523017
Background: A robust decrease in prostate-specific antigen (PSA) in response to androgen deprivation therapy (ADT) has been evaluated as a prognostic factor in patients with metastatic hormone-sensitive prostate cancer (mHSPC)...
24.
Anurag M, Strandgaard T, Kim S, Dou Y, Comperat E, Al-Ahmadie H, et al.
iScience
. 2024 Mar;
27(3):109179.
PMID: 38439961
Urothelial carcinoma (CIS) is an aggressive phenotype of non-muscle-invasive bladder cancer. Molecular features unique to CIS compared to high-grade papillary tumors are underexplored. RNA sequencing of CIS, papillary tumors, and...
25.
Amara C, Kami Reddy K, Yuntao Y, Chan Y, Piyarathna D, Dobrolecki L, et al.
Nat Commun
. 2024 Feb;
15(1):1373.
PMID: 38355560
SMARCB1 loss has long been observed in many solid tumors. However, there is a need to elucidate targetable pathways driving growth and metastasis in SMARCB1-deficient tumors. Here, we demonstrate that...
26.
Myers A, Briganti A, Leibovich B, Lerner S, Moschini M, Roupret M, et al.
Eur Urol Oncol
. 2023 Nov;
7(3):412-420.
PMID: 37980250
Context: Lymphadenectomy during surgery for genitourinary malignancies has varying benefits. Objective: To review contemporary evidence on lymph node dissection in genitourinary cancers. Evidence Acquisition: We performed a collaborative review to...
27.
Lerner S, McConkey D, Tangen C, Meeks J, Flaig T, Hua X, et al.
Clin Cancer Res
. 2023 Nov;
30(2):444-449.
PMID: 37966367
Purpose: The Coexpression Extrapolation (COXEN) gene expression model with chemotherapy-specific scores [for methotrexate, vinblastine, adriamycin, cisplatin (ddMVAC) and gemcitabine/cisplatin (GC)] was developed to identify responders to neoadjuvant chemotherapy (NAC). We...
28.
DiNardo A, Arditi M, Kamat A, Koster K, Carrero S, Nishiguchi T, et al.
Trials
. 2023 Oct;
24(1):636.
PMID: 37794431
Background: A large epidemic, such as that observed with SARS-CoV-2, seriously challenges available hospital capacity, and this would be augmented by infection of healthcare workers (HCW). Bacillus Calmette-Guérin (BCG) is...
29.
Kamat A, Apolo A, Babjuk M, Bivalacqua T, Black P, Buckley R, et al.
J Clin Oncol
. 2023 Oct;
41(35):5437-5447.
PMID: 37793077
Purpose: There is a significant unmet need for new and efficacious therapies in urothelial cancer (UC). To provide recommendations on appropriate clinical trial designs across disease settings in UC, the...
30.
Black P, Tangen C, Singh P, McConkey D, Lucia M, Lowrance W, et al.
Eur Urol
. 2023 Aug;
84(6):536-544.
PMID: 37596191
Background: Although radical cystectomy (RC) is the standard of care for patients with bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC), many patients are ineligible for surgery or elect bladder...